Use in single pill/tablet/capsule of minocycline, fluconazole and atorvastatin in the treatment of multiple sclerosis

Abstract

The present invention has for object the use of minocycline or its equivalent forms, or of any form of tetracycline in combination with Fluconazole or any of its equivalent form with antifungal capacity and atorvastatin or any equivalent form (lipophilic statins) for the preparation of a single compound directed to the treatment of every type of multiple sclerosis or diseases etiopathologically equivalents, whether it be of remitting relapsing or progressive, but anyway degenerative kind, considering the weaker of subject that will receive it as consequence of previous treatments or state of illness. The effectiveness of this combination has been shown from many researches on single components. To date, given the proven efficacy of the individual components, the low toxicity of the same and the long period of the marketing thereof, as well as the observed greater efficiency of the combination of the same used in accordance with the overexposed new mode of use, it can be said that the above-mentioned new compound derived from a combination of minocycline or its equivalent forms, or of any form of tetracycline in combination with Fluconazole or any of its equivalent form with antifungal capacity and atorvastatin or any equivalent form (lipophilic statins), is effective in reduce the incidence of the disease on quality of life of the patient with the designed dosage that never has been determined before.

1 . Use under medical control and prescription of minocycline or its equivalent forms, or of any form of tetracycline in combination with fluconazole or any of its equivalent form with antifungal capacity and atorvastatin or any equivalent form (lipophilic statins) for the preparation of a single compound directed at the treatment of autoimmune-type forms of multiple sclerosis or diseases with common origin to take through a pill, capsule or tablet; 
     
     
         2 . Use under medical control and prescription of the combination of minocycline (100 mg) every 12 hours or its equivalent forms, or of any form of tetracycline, atorvastatin (20 mg) every 12 hours or any equivalent form (lipophilic statins) and fluconazole (50 mg) every 12 hours or any of its equivalent form with antifungal capacity, or their physiologically acceptable forms for the preparation of an oral medicament, in a single tablet or by summation of the three individual substances, for the improvement of quality of life in patients with multiple sclerosis, in whatever form it manifests itself; 
     
     
         3 . Use under medical control and prescription of the combination of minocycline (100 mg) every 12 hours or its equivalent forms, or of any form of tetracycline, atorvastatin (20 mg) every 12 hours or any equivalent form (lipophilic statins), or their physiologically acceptable forms for the preparation of an oral medicament, in a single tablet or by summation of the two individual substances, for the improvement of quality of life in patients suffering from multiple sclerosis, in whatever form it occurs, in case of intolerance of fluconazole; 
     
     
         4 . Use under control and prescription combinations referred to in paragraphs 1, 2 and 3 for the treatment of all forms of multiple sclerosis or neurodegenerative diseases characterized by a demyelinating form and/or intoxication or the presence of viruses such as the 'Epstein Barr virus or other members of the same family of herpesviruses;